Relation between serum myokines and phase II cardiac rehabilitation

Der-Sheng Han, MD, PhD, a,b,c, Ming-Yen Hsiao, MD, c, Tyng-Guey Wang, MD, d, Ssu-Yuan Chen, MD, PhD, d,e,∗ Wei-Shiung Yang, MD, PhD, e,f

Abstract

Patients with coronary heart disease or acute myocardial infarction after cardiac catheterization with stenting referred for phase II cardiac rehabilitation (CR) were grouped according to their preference. Cardio-pulmonary exercise testing (CPET) was used to determine oxygen uptake (VO₂) at peak exercise and anaerobic threshold (AT). The control patients received counseling only while the experiment group received 36 sessions of CR in 3 to 6 months. Exercise physiology parameters and serum myokines (myostatin, insulin-like growth factor-1 (IGF-1), and interleukin-6 (IL-6) were measured pre- and post-rehabilitation.

There were 29 patients in the experiment group and 10 in the control group, with no significant differences in baseline parameters. The experiment group had prominent progress in aerobic capacity and body composition after CR, but their serum myokine concentrations did not change significantly. Serum myostatin is positively correlated to peak VO₂ pre- and post-training, and pretraining AT VO₂ after adjusting for age, sex, and body composition. Serum IGF-1 is positively correlated with grip strength before training.

Serum myostatin level is positively correlated to aerobic capacity, and IGF-1 level is positively correlated to grip strength in cardiac patients receiving CR.

Abbreviations: AT = anaerobic threshold, BMI = body mass index, CHF = congested heart failure, CPET = cardio-pulmonary exercise testing, CR = cardiac rehabilitation, IGF-1 = insulin-like growth factor-1, IL-6 = interleukin-6, VO₂ = oxygen uptake.

Keywords: aerobic metabolism, cardiac rehabilitation, exercise physiology, muscle strength, myokine

1. Introduction

The skeletal muscle has a complex system of homeostasis. Its growth and development are greatly influenced by related myokines such as myostatin, insulin-like growth factor-1 (IGF-1), and interleukin-6 (IL-6). Myostatin, a member of the TGF-β super-family, is a potent negative regulator of skeletal muscle mass. Along with IGF-1, it is proposed as a counter-regulatory molecule for muscle hypertrophy. IGF-1 is an age-related serum protein with insulin-like metabolic activity and growth-control ability. It affects the development of several systems, the musculoskeletal being one of the most important. IGF-1 and IL-6 share common pathways in physiologic regulation. IL-6 can induce the proliferation of muscle stem cells after mechanical stimuli or injury. Some preliminary trials report inconclusive results regarding the immediate effects of exercise-induced changes in these myokines. How exercise influences serum levels of these myokines while increasing strength and possible muscle hypertrophy in the long-term remains controversial.

Recent researches indicate that not only the size and mass but also energy system of skeletal muscle are regulated by myostatin. Muscle fiber conversion and oxidative mitochondrial capacity in myostatin-deficient mice suggest a shift towards anaerobic metabolism in the muscle. Myostatin-deficient mice also have decreased exercise endurance, energy efficiency, and oxygen uptake in vivo. Whether this is due to the development of different muscle types because of congenital myostatin deficiency or if the energy system and aerobic capacity can be directly influenced by serum myokines warrant further elucidation. If the latter is true, a correlation between aerobic capacity and myokines is expected.

Patients with heart diseases often have generalized decreased muscle strength and muscle atrophy, and reduced aerobic capacity, possibly due to de-conditioning and cytokine effects. Exercise, especially strengthening exercise, can maintain the muscle bulk and even reverse the process of muscle atrophy in patients with chronic diseases. Cardiac rehabilitation (CR) is mainly comprised of targeted aerobic conditioning.
and strengthening exercise training, and is a widely accepted standard treatment for cardiac patients.[17] Patients receiving CR have improved aerobic capacity and muscle strength.[18,19]

This study aimed to determine whether the training effects are reflected by changes in serum myokine concentration in a prospective cohort receiving phase II CR. The hypothesis is that myokine concentrations are elevated after CR and that there is direct correlation between myokine concentration and aerobic capacity and muscle strength.

2. Methods

2.1. Patient eligibility

Consecutive cardiac patients referred to the Department of Physical Medicine and Rehabilitation of National Taiwan University Hospital after completing phase I CR program were invited. The inclusion criteria were age >20 years; coronary heart disease diagnosed based on clinical history, electrocardiography, and diagnostic cardiac catheterization; or acute myocardial infarction after cardiac catheterization with stenting. Patients with congested heart failure (CHF), atrial fibrillation/flutter, ventricular bigeminy, active inflammatory disease, malignancy, and cardiac pacemakers were excluded. The diagnosis of CHF was made clinically by a cardiologist based on the Framingham criteria.[20]

The experiment group underwent 36 sessions of hospital-based phase II CR in 3 to 6 months, while the control patients received counseling for exercise as home program only. Both groups received cardio-pulmonary exercise testing (CPET) twice, 3 to 6 months apart. The assignment was according to patient’s choice.

The hospital’s Research Ethic Committee approved the study protocol and all of the participants provided written informed consent. The authors certify that they comply with the ethical standards of the journal.[21]

2.2. Assessments

A CPET was performed and serum myostatin, IGF-1, and IL-6 concentrations were measured before and after the phase II CR program. The blood samples were drawn immediately before and after CPET. Demographic, hemodynamic, and body composition parameters were obtained when the patient received CPET. Measured body habitus and composition parameters included height, weight, body mass index (BMI), lean body mass, and fat percentage. Height was measured to the nearest 0.1cm and weight to the nearest 0.1kg on an electronic scale. Body composition parameters were measured and calculated with a bio-impedance analyzer (Bio Scan 920, Maltron, UK) using standardized protocol.

Hemodynamic parameters other than heart rate and blood pressure were detailed in the following section. The maximal grip strength of bilateral hand of each participant was measured using a digital hand grip dynamometer (Takei Digital Grip Strength Dynamometer, Takei Scientific Instruments Co., Ltd, Niigata, Japan) in a standardized arm and hand position. Three trials were given for familiarization to the instrumentation and technique. The strongest value was adopted for analysis.[22]

2.3. Cardio-pulmonary exercise testing (CPET)

The CPET was performed at least 2 hours after a meal. The test began with 2 minutes of baseline data collection with the patient sitting on the cycle ergometer (Corival, Lode B.V., Zernikepark 16, Groningen, the Netherlands), followed by 2 minutes warm-up cycling with no resistance, and then with load increased by 10 W/min in a ramp protocol. The patient was asked to cycle at 60 to 70 revolutions per min while the workload was gradually increased until volitional exhaustion or termination according to the guidelines of American College of Sports Medicine. The CPET was conducted by a physiatrist.

Blood pressure (TANGO, SunTech Medical Instruments, NC) and continuous 12-lead electrocardiogram were monitored during exercise. Computerized breath-by-breath metabolic system (Quark b2 system, Cosmed srl, Rome, Italy, or Cortex MetaMax 3B system, Leipzig, Germany) was used to analyze the expired air. Exercise cardio-pulmonary parameters, including workload, minute ventilation (VE), oxygen uptake (VO2), carbon dioxide production (VCO2), oxygen pulse, ventilator equivalent for oxygen (Ve/VO2), and ventilatory equivalent for carbon dioxide (Ve/VCO2), were processed.

The anaerobic threshold (AT) was determined by at least two of the following criteria: 1) the Ve/VO2 began to increase systematically without a corresponding increase in Vp/VCO2; 2) the end tidal PO2 began to increase without a decrease in the end tidal PCO2; and 3) departure from linearity for minute ventilation. Two independent observers with experience in CPET determined the ventilatory threshold. The peak oxygen uptake (peak VO2) indicated the highest VO2 value recorded using CPET and was used as the main outcome after CR.

2.4. Cardiac rehabilitation (CR)

The phase I CR program included breathing exercises, splinted cough, range of motion exercises, chest physical therapy, bed mobility exercises, and ambulation training. After discharge, the 3-month phase II CR program was started according to the results of CPET. The exercise sessions were performed 2 to 3 times a week at the outpatient clinic. Each session consisted of both aerobic and resistive exercises as suggested by the American Heart Association on phase II CR.[17] Aerobic training included a 5-minutes warm-up period, a 30-minutes bicycle ergometer and a 5-minutes cool-down period. The workload of training intensity was set at 55% to 70% of the peak VO2 or near the level of the AT obtained from the previous CPET, while the perceived exertion rating was maintained at 12 to 13 on the Borg scale during exercise. The resistance training included 8 to 10 exercises covering the major muscle groups; chest, shoulders, arms, back, abdomen, thigh, lower legs; using a weight that can be lifted for 8 to 10 repetitions.[23] The training course was supervised by a physical therapist and monitored by continuous ECG and blood pressure measurements.

2.5. ELISA of myostatin, IGF-1 and IL-6

Serum myostatin levels were measured using competitive immunoassay kits according to the manufacturer’s protocol (Immunodiagnostik AG, Bensheim, Germany). The full-length myostatin peptide was measured with high specificity. The test sensitivity was 270 pg/mL, while the intra- and interassay variabilities were <10% and <15%, respectively.[24] Briefly, the serum samples were thawed and diluted five times with the dilution buffer provided. After mixing with competitive myostatin antibody solution, the samples were incubated in coated wells for 2 hours at room temperature. After washing, secondary antibody conjugated with peroxidase was added and the mixture was incubated for 1 hour.
The substrate 3,3',5,5'-tetramethylbenzidine for peroxidase was then added. The absorption of each well was read using VersaMAX tunable microplate reader (Molecular Devices, Sunnyvale, CA) at 450nm against 620nm as reference. The 4-parameter logistic regression model was employed to calculate the concentrations with OD values.[21]

Serum IGF-1 levels were measured using ELISA kits according to the manufacturer’s protocol (Mediagnost, Reutlingen, Germany). Sensitivity was 0.09 ng/mL, and the inter- and intra-assay coefficient of variations were 6.8% and 6.7%, respectively.[22] The IL-6 levels were analyzed using sandwiched-type ELISA according to the manufacturer’s instructions (R&D Systems). The inter- and intra-assay coefficient of variations were <10%.[23]

2.6. Statistical analysis

Differences between the experiment and control groups were analyzed using the Mann–Whitney test for ordinal data and Chi-square test for categorical data (sex). The Wilcoxon matched pairs test was employed to analyze the progress of parameters pre- and post-CR.

Data from experiment and control groups were pooled together for analysis of the association between serum myokines and aerobic capacity or muscle strength. Spearman’s correlation coefficient was used to test the correlation. The variables analyzed included pre- and post-training serum myokines levels, as well as increments of levels, peak VO₂, AT VO₂, and grip strength. Subgroup analysis was also performed for the experiment group only.

Parameters with significant correlations were further analyzed by linear regression model adjusted for age, sex, and body composition. Possible determinants of peak VO₂, AT VO₂, and mean bilateral grip strength were identified. The independent variables were myostatin, IGF-1, and IL-6. Significance level was set at $P < .05$. All statistical tests were performed using the SPSS 11.5 (SPSS Inc. Chicago, Illinois).

3. Results

3.1. Baseline data

Of the 39 patients with coronary heart disease included, nine had a history of acute myocardial infarction. The time from cardiac catheterization and stenting to enrollment ranged from 45 days to 1 year. The control group (n=10) and the experiment group (n=29) had no differences in age, sex, ratio, body composition, exercise physiology, and serum myokine concentrations at baseline (Table 1, Supplemental Data, http://links.lww.com/MD/B654).

3.2. Progress after CR

After CR, the experiment group had significantly more progress in peak VO₂, AT VO₂, and body fat percentage compared to the control group. However, serum myokine concentrations did not significantly change after CR in both groups (Table 2, Supplemental Data, http://links.lww.com/MD/B654). The experiment group showed >20% improvement in peak VO₂ and 14% improvement in AT VO₂ regardless of adjustment by weight. Decreased body fat percentage and increased lean body mass were also noted. There was a trend towards progress in grip strength but this did not reach statistical significance ($P = .093$ and .064 for the right and left sides, respectively).

3.3. Correlations between serum myokines and aerobic capacity or muscle strength

Pooling the data of the experiment and control groups revealed significant positive unadjusted correlation between pretraining myostatin and pretraining peak VO₂ ($P = .018$) and increased peak VO₂ ($P = .021$); between pre- or post-training IGF-1 and increased AT VO₂ ($P = .013$ and .040, respectively). Furthermore, there was a significant positive correlation between pre- or post-training IGF-1 and grip strength ($P = .001$ and .032, respectively). There were no significant correlations between myokines and other parameters of exercise physiology.

By the linear regression model adjusted for age, sex, and body composition (percentage of body fat), myostatin was a determinant of pretraining VO₂. Serum IGF-1 level is positively correlated to pretraining aerobic capacity after adjusting for age, sex, and body composition. Myostatin level is positively correlated to pre- and post-training peak VO₂ and pretraining AT VO₂. Serum IGF-1 level is positively correlated to pretraining grip strength.

4. Discussion

This prospective cohort study reveals that patients receiving phase II CR have significantly improved resting blood pressure, body composition, and aerobic capacity. Serum myostatin, IL-6, and IGF-1 levels do not change significantly post-CR. In the cross-sectional observation part, serum myostatin level is positively correlated to aerobic capacity after adjusting for age, sex, and body composition. Myostatin level is positively correlated to pre- and post-training peak VO₂, and pretraining AT VO₂. Serum IGF-1 level is positively correlated to pretraining grip strength.

Table 1

|                      | Control | Experiment | P value |
|----------------------|---------|------------|---------|
| Number               | 10      | 29         |         |
| Age, year            | 58.8±7.0| 56.4±10.8  | .469    |
| Gender, M/F          | 8/2     | 26/3       | .381    |
| Height, cm           | 165.0±7.0| 166.0±8.0  | .498    |
| Weight, kg           | 72.6±10.6| 73.6±14.2  | .936    |
| BMI, kg/m²           | 28.6±3.4| 26.0±3.9   | .748    |
| Lean body mass, kg   | 53.2±8.4| 55.0±9.6   | .621    |
| Fat percentage, %    | 27.0±6.2| 26.0±6.1   | .761    |
| Resting HR, beat/min | 63.2±8.1| 69.4±12.0  | .367    |
| Resting SBP, mm Hg   | 116.1±1.0| 123.1±19.1 | .664    |
| Resting DBP, mm Hg   | 71.3±10.1| 73.0±10.4  | .499    |
| Peak VO₂, mL/min     | 1530.2±412.4| 1452.5±441.0 | .368    |
| Peak VO₂, mL/min/kg  | 21.1±5.0| 19.7±4.7   | .385    |
| AT VO₂, mL/min       | 972.1±171.3| 1062.3±342.2 | .621    |
| AT VO₂, mL/min/kg    | 14.2±2.2| 14.5±3.6   | .287    |
| Grip strength, kg R  | 34.0±10.0| 35.0±8.0   | .757    |
| Grip strength, kg L  | 34.0±9.0| 34.0±8.0   | .891    |
| IGF-1, ng/mL         | 250.6±52.0| 290.0±77.0  | .187    |
| IL-6, 10⁻¹⁰ ng/mL    | 1.4±0.7 | 1.2±0.6    | .520    |
| Myostatin, ng/mL     | 25.0±23.0| 23.0±18.0  | .923    |

AT = anaerobic threshold, BMI = body mass index, DBP = diastolic blood pressure, F = female, HR = heart rate, IGF-1 = insulin-like growth factor-1, IL-6 = interleukin-6, L = left, M = male, R= right, SBP = systolic blood pressure, VO₂ = oxygen uptake.

The values are expressed in mean± standard deviation.

* Comparisons were made using Mann–Whitney test.

Han et al. Medicine (2017) 96:16 www.md-journal.com
Muscle growth and differentiation are known to be regulated by muscle-related cytokines. Myostatin, primarily expressed in skeletal muscles, has been proposed as a “chalone” of muscle tissue or as a counter-regulatory molecule along with IGF-1 for muscle hypertrophy.11,28 Myostatin knockout mice had larger skeletal muscle size compared to the wild type.14 Myostatin-inhibiting monoclonal antibodies in mdx (Duchenne muscular dystrophy) mice show improved dystrophic symptoms with increasing muscle mass and myofibril size. On the other hand, excessive transgenic myostatin in mice lead to significant cachexia.21 Recently, accumulated evidence reveals that myostatin plays an important role in modulating the energy system of muscle aside from regulating muscle growth. There is a conversion of slow oxidative (type I) fiber to fast glycolytic (type IIb) fiber, as well as reduced oxidative mitochondrial capacity in myostatin deficient mice, suggesting a shift toward anaerobic metabolism in the muscle.10,11 Mousiel et al12 further indicate decreased exercise endurance, energy efficiency, and oxygen uptake in myostatin deficient mice. Whether the serum level of myostatin directly reflects aerobic capacity remain

### Table 2

| Progress of parameters in body habitus and composition, exercise physiology, and myokines concentration in the experiment (after hospital-based cardiac rehabilitation) and control (after home program) groups. |
|---|---|---|---|
| | Control | Experiment | P value |
| Weight, kg | 0.2±1.1 | 0.3±1.5 | –0.3±2.3 | 0.4±3.2 |
| BMI, kg/m² | 0.0±0.4 | 0.0±1.5 | –0.0±0.9 | 0.0±3.4 |
| Lean body mass, kg | –0.6±1.6 | 1.1±3.0 | 1.4±3.7† | 2.5±6.7 |
| Fat percentage, % | 1.2±2.0 | 4.3±7.6 | –2.5±4.8† | –9.6±18.3 |
| Resting HR, beat/min | 8.0±13.0 | 13.4±20.4 | 2.0±11.1 | 2.5±16.3 |
| Resting SBP, mm Hg | 1.0±12.0 | 0.4±10.6 | –8.1±13.2† | –6.8±10.5 |
| Rest DBP, mm Hg | 1.0±8.8 | 1.4±11.9 | 3.0±8.9 | 4.1±12.3 |
| Peak vO₂, mL/min | 35.0±177.0 | 2.3±11.6 | 320.3±204.1† | 22.1±14.1 |
| Peak vO₂, mL/min/kg | 0.4±2.2 | 2.1±10.4 | 4.5±2.7† | 22.9±13.7 |
| AT vO₂, mL/min | 5.0±94.0 | 0.5±9.7 | 152±198† | 14.3±18.7 |
| AT vO₂, mL/min/kg | 0.1±15.5 | 0.5±10.4 | 2.1±2.5† | 14.3±17.4 |
| Grip strength, kg R | 1.1±4.9 | 3.3±14.3 | 1.6±4.2 | 4.6±12.0 |
| Grip strength, kg L | 0.4±3.5 | 1.2±10.2 | 1.0±4.4 | 3.0±12.9 |
| IGF-1, ng/mL | 20.4±65.9 | 8.0±17.9 | 15.9±68.9 | 5.5±23.8 |
| IL-6, 10⁻³ ng/mL | –0.1±0.6 | –11.4±64.7 | 0.3±1.5 | 29.6±149.6 |
| Myostatin, ng/mL | –1.7±16.8 | –6.8±67.2 | –0.3±17.1 | –1.5±74.1 |

AT = anaerobic threshold, BMI = body mass index, DBP = diastolic blood pressure, HR = heart rate, IGF-1 = insulin-like growth factor-1, IL-6 = interleukin-6, SBP = systolic blood pressure, vO₂ = Oxygen uptake. The values are expressed in mean ± standard deviation.

† The percentage of progress was as compared with pretraining status.

* Values with P < .01 by Wilcoxon matched pairs test, by comparison between pre-and post-training status.

* Values with P < .01 by Mann-Whitney test by comparisons between the experiment and control groups.

### Table 3

Linear regression model for predicting aerobic capacity and grip strength adjusted by age, sex, and body composition of the participants.

| Time of measurement | Dependent variables | Independent variables | Unadjusted regression coefficients | Adjusted regression coefficient β | P value |
|---|---|---|---|---|---|
| Pretraining | Peak vO₂ | Myostatin | 0.14 | 0.15† | <.001 |
| | | IGF-1 | 0.02 | –0.01 | .695 |
| | | IL-6 | –2.28 | –0.31 | .788 |
| | AT vO₂ | Myostatin | 0.09 | 0.10† | .002 |
| | | IGF-1 | 0.01 | .00 | .922 |
| | | IL-6 | –1.35 | 0.13 | .890 |
| | Grip strength | Myostatin | 0.07 | –0.01 | .908 |
| | | IGF-1 | 0.06 | .04 | .010 |
| | | IL-6 | –3.04 | –0.66 | .616 |
| Post-training | Peak vO₂ | Myostatin | 0.09 | 0.13 | .007 |
| | | IGF-1 | 0.02 | 0.01 | .354 |
| | | IL-6 | –0.00 | 0.41 | .371 |
| | AT vO₂ | Myostatin | 0.04 | 0.05 | .301 |
| | | IGF-1 | 0.01 | .00 | .692 |
| | | IL-6 | 0.13 | 0.43 | .206 |
| | Grip strength | Myostatin | –0.06 | –0.07 | .333 |
| | | IGF-1 | 0.03 | 0.01 | .462 |
| | | IL-6 | 0.71 | 0.39 | .573 |

AT = anaerobic threshold, CI = confidence interval, IGF-1 = insulin-like growth factor-1, IL-6 = interleukin-6, LL = lower limit, UL = upper limit, vO₂ = oxygen uptake.

† P < .01 for adjusted linear regression were shown in bold.
mostly unknown. To date, this is the first study that provides evidence that myostatin is positively correlated to aerobic capacity in cardiac patients receiving phase II CR.

CR can increase VO2 by increasing stroke volume, lowering resting heart rate and blood pressure, and improving physical fitness such as increasing skeletal muscle mass and strength, with decreasing body fat percentage. This study also shows that the patients receiving phase II CR have significantly improved parameters of exercise physiology and body composition. However, the corresponding serum myostatin, IL-6, and IGF-1 levels do not change.

Previous studies indicate myostatin changes in response to both muscle growth and exercise. In the “accelerator-brake” model or the “yin-yang” concept coined by Mak and Rotwein and Han et al, myostatin and IGF-1 act as counter-regulatory molecules for muscle hypertrophy. The myostatin expression increases, as a brake, to limit the over-speeding growth of muscle tissue. On the other hand, two small trials have shown that the expression of myostatin decrease after 6 months of aerobic exercise in obese or insulin-resistant participants. One possible reason is that aerobic exercise, in contrast to resistance training, may not be enough stimuli for muscle hypertrophy and growth. Hence, no myostatin “brake” is needed. Furthermore, aerobic exercise affects not only muscle metabolism but also body composition, which may further influence serum level of myostatin. The participants in the present study received both aerobic and resistant training. Thus, changes in serum myostatin may not be explained by any of the previous and further research is warranted for a conclusive result.

In the present study, IGF-1 and IL-6 also do not change significantly after CR. There is positive association between pretraining IGF-1 and grip strength, which is consistent with a previous report. Antecedent trials about exercise-related changes of IL-6 and IGF-1 appear to be inconclusive. Some indicate short-lasting increases in circulating IL-6 from muscle after exercise. IL-6 mRNA expression increases immediately after exercise in muscle biopsy samples, but the long-term effect of exercise training on IL-6 level remain unknown. Regarding IGF-1 changes after exercise, some report a transient increase while others show no changes. Trials are preliminary and include limited case numbers. In a randomized control trial with 319 participants, 16 weeks of aerobic exercise provide minimal or no effect on serum IGF-1. The response in these myokines after CR has multiple confounding factors, with age and body composition as the most important. In the present study, there is no correlation between these factors and myokines pre- and post-training (data not shown). In addition, positive correlations between aerobic capacity and myostatin and between grip strength and IGF-1 remain after adjustment for these confounders.

This study has several limitations. The positive association between exercise physiology and myokines is from cross-section observations and does not imply any causal-relationship. This study also has a small sample size and may have inadequate test power, leading to insignificance. Furthermore, there are large interindividual variations in exercise physiology parameters and myokine levels, but no repeated measurements have been done and possible circadian fluctuations are not accounted for. Little is known regarding the time frame of the “accelerator-brake” model. The time of measurement of the myokines may not reflect steady state. Serial sampling and long-term follow-up is required for further clarification. Lastly, selection bias cannot be avoided by convenient sampling in a medical center. There should be caution when making generalizations. Further large-scale prospective studies with long-term follow-up are warranted to delineate muscle-related myokine changes in response to exercise training.

5. Conclusions

Serum myostatin level is positively correlated to aerobic capacity, and IGF-1 level is positively correlated to grip strength in cardiac patients receiving CR. Serum myostatin, IL-6, and IGF-1 do not significantly change after CR, however, further studies are warranted to delineate myokines changes in response to exercise training.

References

[1] McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 1997;387:83–90.
[2] Zimmers TA, Davies MV, Komiaris LG, et al. Induction of Cachexia in mice by systemically administered myostatin. Science 2002;296:1486–8.
[3] Gausin V, Depre C. Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res 2005;68:347–9.
[4] Grimbarg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1–9.
[5] Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle 2011;1:4.
[6] O’Connor JC, McCusker RH, Sirle K, et al. Regulation of IGF-1 function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol 2008;252:91–110.
[7] McKay BR, De Lisio M, Johnston AP, et al. Association of interleukin-6 signalling with the muscle stem cell response following muscle-lengthening contractions in humans. PLoS One 2009;4:e6027.
[8] Capron J, Brasil JA, Mohan S, et al. Effect of brief exercise on circulating insulin-like growth factor I. J Appl Physiol 1994;76:2490–6.
[9] Drentel JP, Van Uum SH, Van Deuren M, et al. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-α and IL-1 beta production. J Appl Physiol 1995;79:1497–503.
[10] Hennebre A, Berry C, Sinuet V, et al. Myostatin regulates fiber-type composition of skeletal muscle by regulating MEF2 and MyoD gene expression. Am J Physiol 2009;296:C525–34.
[11] Balgand C, Gilson H, Menard JC, et al. Functional assessment of skeletal muscle in intact mice lacking myostatin by concurrent NMR imaging and spectroscopy. Gene Ther 2010;17:328–37.
[12] Mossel E, Reilzani K, Mille-Hamard L, et al. Myostatin is a key mediator between energy metabolism and endurance capacity of skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2014;307:R444–54.
[13] Toth MJ, Gorlich-SH, Fisher ML, et al. Skeletal muscle atrophy and peak oxygen consumption in heart failure. Am J Cardiol 1997;79:1267–9.
[14] Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992;85:1364–73.
[15] Zinna EM, Yarasheki KE. Exercise treatment to counteract protein wasting of chronic diseases. Curr Opin Clin Nutr Metab Care 2003;6:87–93.
[16] Pu CT, Johnson MT, Forman DE, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol 2001;90:2341–50.
[17] Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity, in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2005;111:369–76.
[18] Arthur HM, Gunn E, Thorpe KE, et al. Effect of aerobic vs combined aerobic-strength training on 1-year, post-cardiac rehabilitation outcomes in women after a cardiac event. J Rehabil Med 2007;39:730–5.
[19] Adams KJ, Baradell KL, Swank AM, et al. Combined high-intensity strength and aerobic training in diverse phase II cardiac rehabilitation patients. J Cardiopulm Rehabil 1999;19:209–15.
[20] Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(4 suppl A):6A–13A.
